INBX - NASDAQ

Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc.

INBXยทNASDAQ

$95.22

+1.7%
HealthcareBiotechnology

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$1.40B
EPS-9.0400
P/E Ratio-10.53
Earnings Date08/12/2026
Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. Fair Value Envelope

INBX ยท NASDAQ

Our analysis suggests that INBX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $95.22, this represents a potential HIDDEN relative to our calculated worth for Inhibrx Biosciences, Inc..

HIDDEN
Intrinsic Value
Current Price: $95.22

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$5.1B
+ Cash & Equivalents$124.2M
Firm Value-$5.0B
- Debt$107.0M
Equity Value-$5.1B
/ Shares Outstanding14,485,016B
DCF Value-$354
OVERVALUED BY 472%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$174.1M
-$233.4M
-$313.0M
-$419.7M
-$562.9M
-$754.8M
-$1.0B
-$1.4B
-$1.8B
-$2.4B
Maintenance CapEx
-$8.3K
-$11.1K
-$15.0K
-$20.1K
-$26.9K
-$36.1K
-$48.4K
-$64.8K
-$87.0K
-$116.6K
Owner Earnings
-$174.1M
-$233.4M
-$313.0M
-$419.8M
-$562.9M
-$754.9M
-$1.0B
-$1.4B
-$1.8B
-$2.4B
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$161.2M
-$200.1M
-$248.5M
-$308.5M
-$383.1M
-$475.7M
-$590.7M
-$733.4M
-$910.6M
-$1.1B
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your INBX research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.